Neurology

The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.
[[thumbnail_alt_text]]
Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.
[[thumbnail_alt_text]]
Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.
 
[[thumbnail_alt_text]]
Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.
 
[[thumbnail_alt_text]]
Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.
[[thumbnail_alt_text]]
Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
 
[[thumbnail_alt_text]]
Lasmiditan (Reyvow, Eli Lilly) resolved pain and most bothersome symptoms within 2 hours of treatment in patients with migraine.
 
[[thumbnail_alt_text]]
Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.
[[thumbnail_alt_text]]
The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.
[[thumbnail_alt_text]]
Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.
 
[[thumbnail_alt_text]]
New updates to immunization guidelines in multiple sclerosis outline recommendations on vaccination decisions for patients.